Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab

References

• Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 2010;47:170–179.
   PubMed Web of Science ®Google Scholar
• Mogensen TH, Bernth-Jensen JM, Petersen CC, et al. Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab. BMC Blood Disorders 2013;13:4.
   Google Scholar
• Kimby E. Tolerability and safety of rituximab. Cancer Treat Rev 2005;31:456–473.
   PubMed Web of Science ®Google Scholar
• Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers 2015;7:305–328.
   PubMed Web of Science ®Google Scholar
• Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998;10:252–258.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777–783.
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Zoppoli G, Massucco C, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-hodgkin's Lymphoma patients treated with rituximab-containing regimens. J Immunol 2011;186:6044–6055.
   PubMed Web of Science ®Google Scholar
• Aksoy S, Dizdar Ö, Hayran M, et al. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma 2009;50:357–365.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496–1502.
   PubMed Web of Science ®Google Scholar
• Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006;38:433–436.
   PubMed Web of Science ®Google Scholar
• Lim SH, Zhang Y, Wang Z, et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant 2004;35:207–208.
   PubMed Web of Science ®Google Scholar
• Nishio M, Endo T, Fujimoto K, et al. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol 2005;75:527–529.
   PubMed Web of Science ®Google Scholar
• Nishio M, Endo T, Fujimoto K, et al. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur J Haematol 2009;82:143–147.
   PubMed Web of Science ®Google Scholar
• De La Torre I, Leandro MJ, Valor L, et al. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology 2012;51:833–840.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Kopyltsova Y, Khokhar A, et al. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract 2014;2:594–600.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Liboy I, Pavia O, et al. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006;17:1424–1427.
   PubMed Web of Science ®Google Scholar
• Roberts DM, Jones RB, Smith RM, et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 2015;57:60–65.
   PubMed Web of Science ®Google Scholar
• Karmacharya P, Poudel DR, Pathak R, et al. Rituximab-induced serum sickness: A systematic review. Semin Arthritis Rheumatism 2015;45:334–340.
   PubMed Web of Science ®Google Scholar
• Diwakar L, Gorrie S, Richter A, et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 2010;63:275–277.
   PubMed Web of Science ®Google Scholar
• van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364–4369.
   PubMed Web of Science ®Google Scholar
• Imashuku S, Teramura T, Morimoto A, et al. Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein–Barr virus-associated lymphoproliferative disease. Bone Marrow Transplantat. 2004;33:129–130.
   PubMed Web of Science ®Google Scholar
• Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 2009;146:120–122.
   PubMed Web of Science ®Google Scholar
• Miles SA, McGratten M. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol 2005;23:247–248.
   PubMed Web of Science ®Google Scholar
• Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013;13:106–111.
   PubMed Web of Science ®Google Scholar
• Filanovsky K, Shvidel L, Shtalrid M, et al. Predictive factors to hypogammaglobulinemia and non-neutropenic infection complications after rituximab/chemotherapy treatment. Blood 2007;110:1288.
   Web of Science ®Google Scholar
• Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysis. Arthritis Rheum 2007;56:3896–3908.
   PubMed Web of Science ®Google Scholar
• Marco H, Smith RM, Jones RB, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskeletal Disord. 2014;15:178.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven R, Bessette L, Emery P. Long-term safety of rituximab: long-term follow-up of the RA clinical trials and retreatment population. J Rheumatol 2010;37:558–567.
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Li L, Kambham N, et al. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008;8:2607–2617.
   PubMed Web of Science ®Google Scholar
• Makatsori M, Kiani-Alikhan S, Manson A, et al. Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes. QJM 2014;107:821–828.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Daikos G, Boumpas D, et al. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011;15:e2–e16.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheumatol. 2010;62:2625–2632.
   Web of Science ®Google Scholar
• Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy, Asthma Immunol 2005;94:S1–S63.
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Baars JW, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257–2259.
   PubMed Web of Science ®Google Scholar
• Lim SH, Esler WV, Zhang Y, Zhang J, Periman PO, Burris C, et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma 2008;49:152–153.
   PubMed Web of Science ®Google Scholar
• Mouthon L, Fermand J-P, Gottenberg J-E. Management of secondary immune deficiencies: what is the role of immunoglobulins? Curr Opin Allergy Clin Immunol 2013;13:S56–S67.
   PubMed Web of Science ®Google Scholar
• Kanbayashi Y, Nomura K, Fujimoto Y, et al. Risk factors for infection in haematology patients treated with rituximab. Eur J Haematol 2009;82:26–30.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47:1013–1017.
   PubMed Web of Science ®Google Scholar
• Curtis J, Yang S, Patkar N, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res 2014;66:990–997.
   Web of Science ®Google Scholar
• Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology 2013;52:2041–2047.
   PubMed Web of Science ®Google Scholar
• Castelli R, Ferraris L, Pantaleo G, et al. High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy. Dig Liver Dis 2016;48:1394–1397.
   PubMedGoogle Scholar
• Grisariu S, Vaxman I, Gatt M, et al. Enteroviral infection in patients treated with rituximab for non‐Hodgkin lymphoma: a case series and review of the literature. Hematol Oncol 2016; doi:10.1002/hon.2365.
   Google Scholar
• Tuccori M, Focosi D, Blandizzi C, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist 2010;15:1214–1219.
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834–4840.
   PubMed Web of Science ®Google Scholar
• Kamar N, Milioto O, Puissant‐Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney‐transplant patients. Am. J. Transplant 2010;10:89–98.
   PubMed Web of Science ®Google Scholar
• Molloy ES, Calabrese CM, Calabrese LH. The risk of progressive multifocal leukoencephalopathy in the biologic era: prevention and management. Rheum Dis Clin N Am 2017;43:95–109.
   PubMed Web of Science ®Google Scholar
• Rituxan warning. FDA Consum 2007;41:3.
   Google Scholar
• Nishio M, Fujimoto K, Yamamoto S, et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol 2006;77:226–232.
   PubMed Web of Science ®Google Scholar
• Lin P-C, Hsiao L-T, Poh S-B, et al. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Ann Hematol 2007;86:95–100.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Holte H, Fosså A, et al. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007;92:139–140.
   PubMed Web of Science ®Google Scholar
• https://www.gene.com/download/pdf/rituxan_prescribing.pdf
   Google Scholar
• Mok CC. Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis 2015;18:154–163.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008;358:676–688.
   PubMed Web of Science ®Google Scholar
• Querol L, Rojas-García R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol-Neuroimmunol Neuroinflammation 2015;2:e149.
   PubMed Web of Science ®Google Scholar
• Desai J, Ramos-Platt L, Mitchell WG. Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies and questions. Ann Indian Acad Neurol 2015;18:327–330.
   PubMed Web of Science ®Google Scholar
• Michel M, Terriou L, Roudot‐Thoraval F, et al. A randomized and double‐blind controlled trial evaluating the safety and efficacy of rituximab for warm auto‐immune hemolytic anemia in adults (the RAIHA study). Am J Hematol 2017;92:23–27.
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004;103:2925–2928.
   PubMed Web of Science ®Google Scholar
• Froissart A, Veyradier A, Hié M, et al. Microangiopathies FRCfT. Rituximab in autoimmune thrombotic thrombocytopenic purpura: a success story. Eur J Intern Med 2015;26:659–665.
   PubMed Web of Science ®Google Scholar
• Stiakaki E, Perdikogianni C, Thomou C, et al. Idiopathic thrombocytopenic purpura in childhood: twenty years of experience in a single center. Pediatr Int 2012;54:524–527.
   PubMed Web of Science ®Google Scholar
• Bader-Meunier B, Aladjidi N, Bellmann F, et al. Rituximab therapy for childhood Evans syndrome. Haematologica 2007;92:1691–1694.
   PubMed Web of Science ®Google Scholar
• Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 2009;114:3167–3172.
   PubMed Web of Science ®Google Scholar
• Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab. Arch Neurol 2008;65:1443–1448.
   PubMedGoogle Scholar
• Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2014;100:422–431.
   PubMed Web of Science ®Google Scholar
• Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013;62:1607–1615.
   PubMed Web of Science ®Google Scholar
• Pranzatelli MR, Tate ED, Travelstead AL, et al. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 2005;115:e115–e119.
   PubMed Web of Science ®Google Scholar
• Khosroshahi A, Wallace Z, Crowe J, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015;67:1688–1699.
   PubMed Web of Science ®Google Scholar
• Lunn M, Nobile‐Orazio E. Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies. Cochrane Libr 2016;10:CD002827.
   Google Scholar
• Bergua J, Cabrera C, Arteta E, et al. Rituximab in CD20 positive multiple myeloma. Leukemia 2008;22:1082–1085.
   PubMed Web of Science ®Google Scholar
• Santos-Lozano A, Morales-Gonzalez A, Sanchís-Gomar F, et al. Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials. Crit Rev Oncol/Hematol 2016;105:118–126.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Logan B, Wang D, et al. Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009;145:816–824.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772–1779.
   PubMed Web of Science ®Google Scholar
• He Y, Shimoda M, Ono Y, et al. Persistence of autoreactive IgA-secreting B cells despite multiple immunosuppressive medications including rituximab. JAMA Dermatol 2015;151:646–650.
   PubMed Web of Science ®Google Scholar
• Fluge Ø, Mella O. Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurol 2009;9:28.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Laurent G, et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. J Clin Oncol 2011;29:8004.
   Google Scholar
• Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 2006;21:1698–1700.
   PubMed Web of Science ®Google Scholar
• Reddy V, Martinez L, Isenberg DA, et al. Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: Long‐term effects on serum immunoglobulins. Arthritis Care Res 2016;69(6):857–866.
   Web of Science ®Google Scholar
• Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 2008;87:393–397.
   PubMed Web of Science ®Google Scholar